Please try another search
AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California.
Name | Age | Since | Title |
---|---|---|---|
Vikram Malik | 60 | 2020 | President & Director |
Eric G. Carter | 71 | 2023 | Independent Director |
Shelley B. Thunen | 69 | 2023 | Independent Director |
Robert J. Palmisano | 78 | 2023 | Independent Director |
Jost Fischer | 69 | 2017 | Chairman |
Seongsoo Park | 48 | 2024 | Director |
Marc Forth | 53 | 2019 | Principal Financial Officer, President, CEO & Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review